Sep 13, 2022 Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
Aug 3, 2022 Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
Jul 5, 2022 Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
